Navigation Links
Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Date:10/30/2012

PALO ALTO, Calif., Oct. 30, 2012 /PRNewswire/ -- Neuraltus Pharmaceuticals, a private biopharmaceutical company developing novel therapies for rare neurological disorders, announced today top-line results from the Company's Phase 2 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).  Study efficacy results demonstrated positive trends in slowing the rate of disease progression, ranging from 13 to 19% in multiple parameters of clinical benefit, although these pre-defined endpoints did not reach statistical significance.  Importantly, according to a post hoc analysis, a greater percentage of patients receiving NP001 experienced a halt in disease progression which reached statistical significance when compared to the combination of concurrent and matched historical (placebo) controls.  Further, NP001 was found to be safe and well-tolerated.  Based on these results, and after a meeting with the FDA, Neuraltus is planning a Phase 3 clinical program that is expected to begin in the second half of 2013.

"ALS is a rare neurodegenerative disease that typically leads to respiratory failure and death within five years of diagnosis.  The results from this study with NP001 are most encouraging, as halting or slowing the rate of disease progression, in a subset of patients, as this study suggests, would translate into a clear clinical benefit for these patients," commented Robert G. Miller, M.D., of California Pacific Medical Center, the Principal Investigator of the study.

NP001 is a small molecule regulator of macrophage activation.  Aberrant macrophage activation is believed to be a significant contributor to the pathology underlying ALS and other neurodegenerative diseases.  Neuraltus' NP001 is designed to restore the normal functioning of macrophages within the central nervous system.

The multi-center, double-blind, placebo-controlled, Phase 2 study enro
'/>"/>

SOURCE Neuraltus Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Research and Markets has announced the ... of Pharmaceutical Equipment Market in China, 2014-2018" report ... Trend Forecast of Pharmaceutical Equipment Market in ... pharmaceutical equipment industry in the aspects of ... business performance of domestic major enterprises, as well as ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" ... announced today that it intends to release its financial ... ended June 30, 2014 after market trading ends on ... scheduled a conference call for 4:30 p.m. U.S. EDT ... at 6:30 a.m. AEST), to review the Company,s financial results, ...
(Date:8/29/2014)... 2014  Pacific Medical Data Solutions is excited to ... . The main website, along with the site,s blog, ... services and content relevant to the medical billing industry. ... viewers can now better understand how PMDS products help ... create a more visible platform about medical billing best ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2PMDS Announces New Website 2
... 2011 Mylan Inc. (Nasdaq: MYL ) ... Matrix Laboratories Limited) has received approval for three antiretroviral ... Health Organization,s (WHO) Prequalification of Medicines Programme. The products ... Tablet, 100 mg (heat-stable), and Tenofovir Disoproxil Fumarate and ...
... Medical imaging has revolutionized healthcare and is essential ... Modern equipment and protocols ensure that patients, physicians, and ... radiation, while still providing accurate results and diagnostic information. ... medical procedure must be balanced with the benefits of ...
Cached Medicine Technology:Mylan Receives WHO Approval for Innovative 'Second-Line-in-a-Box' HIV/AIDS Treatment 2Mylan Receives WHO Approval for Innovative 'Second-Line-in-a-Box' HIV/AIDS Treatment 3Mylan Receives WHO Approval for Innovative 'Second-Line-in-a-Box' HIV/AIDS Treatment 4AAPM Cautions that Patients Should Not Forgo Essential Medical Imaging 2
(Date:8/29/2014)... 29, 2014 Dr. Parsa Mohebi M.D. has ... hair loss achieve great results in hair transplantation. One ... Transplant , an FUE method that harvests facial hair for ... method lets patients whose hair loss classification is 5 and ... is a great alternative for those advanced hair loss patients ...
(Date:8/29/2014)... Highly regarded audiologist , Dr. Mary Ann Larkin has ... four reports are titled:, , Revealing the Truth ... , The Top 5 Things You Should Know Before ... in Children , Dr. Mary Anne Larkin choose to ... confusion and misinformation about each them. The reports are available ...
(Date:8/29/2014)... 2014 Pursuing its deepest desires to ... unveil a stunning new design that promises to redefine ... highly notable surrogacy platform has witnessed a 42 percent ... visitors a month, the FindSurrogateMother.com community is formed by ... common goal — the precious gift of life. , ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- If you have bunions, taking ... treatment later, an expert says. A bunion is a ... when bone or tissue moves out of place and extends ... can cause debilitating pain and may require surgery to correct, ... Medical Center in Freehold, N.J. To prevent bunions, avoid ...
(Date:8/29/2014)... August 29, 2014 - Despite US Preventive Services ... are many barriers, several of which may be ameliorated ... researchers at NYU Langone Medical Center published online August ... Medicine ( JGIM ). , David Levine, MD, ... Internal Medicine at NYU Langone, and colleagues found that ...
Breaking Medicine News(10 mins):Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Take Steps to Control Bunions 2Health News:Options for weight loss your primary care doctor might not know about 2
... Than 1,500 YMCAs Get Their Communities Moving During Week-Long Event; ... YMCAs Aim to Keep Communities Active Year-Round, WASHINGTON, ... logged during "America On the Move Week with the YMCA" ... More than 1,500 YMCAs nationwide reached out to their ...
... With an eye on curing diabetes, scientists at Washington ... transplanted embryonic pig pancreatic cells destined to produce insulin ... for risky immune suppression drugs that prevent rejection. , ... earliest stages of developing into pancreatic tissues. Within several ...
... it instead of traditional immune globulin injection , , THURSDAY, ... hepatitis A with the hepatitis A vaccine is as ... of immune globulin, a new study found. , Based ... and Prevention,s Advisory Committee on Immunization Practices now recommends ...
... Union Urges Congress to Enact HR 1174 (Murphy) ... WASHINGTON, Oct. 18 A new study that,estimates ... virulent,antibiotic-resistant infection acquired mostly in the hospital underscores,the ... patient infection,rates, according to Consumers Union, the nonprofit ...
... device evaluated in cadaver by leading spine ... ... CoreSpine Technologies LLC, an,emerging spinal device company located in Minneapolis, Minnesota ... first product in development is a complete nucleus removal,device that seeks ...
... Conseco, Inc. (NYSE:,CNO) will report results for the ... 31, 2007. The company will host a conference call ... November 1, 2007. The web cast of the ... the company,s website as follows:, http://investor.conseco.com . Listeners should ...
Cached Medicine News:Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 2Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 3Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 4Health News:Cross-species transplant in rhesus macaques is step toward diabetes cure for humans 2Health News:Cross-species transplant in rhesus macaques is step toward diabetes cure for humans 3Health News:Hepatitis A Vaccine Best Bet to Treat Virus 2Health News:Hepatitis A Vaccine Best Bet to Treat Virus 3Health News:Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital-Acquired Infections 2Health News:Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital-Acquired Infections 3Health News:Initial Evaluation of New Nucleus Removal Device Provides Promising Results 2
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
... C Dermatome - reaching a new evolutionary plateau. ... to operate in the pulse mode, or to ... entire instrument and hose assembly is autoclavable and ... 2-, 3-, or 4-inch widths. Simply select the ...
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator (Fenzl), blunt tip angled 45, 12.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge ind...
Medicine Products: